Monograph
C03AB01 - Bendroflumethiazide and Potassium |
Propably not porphyrinogenic |
PNP |
Rationale
Sulfonamide type of drug. Clinical experience points to non-porphyrinogenicity. There are references that warn against the drug. Combined with potassium chloride.
Therapeutic characteristics
Thiazide diuretic and antihypertensive.
Metabolism and pharmacokinetics
The major part of the drug is eliminated via non-renal mechanisms, only 30 % excreted in unchanged form in urine. More specific data on metabolism are lacking. No observations of CYP interaction. Bendroflumethiazide is a sulfonamide type drug, a drug group often incriminated in acute porphyric attacks. Combined with potassium chloride.
Personal communication
Thunell, patient report (n=1): tolerated. Andersson, patient report (n=11): tolerated.
Published experience
None.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Pharmacokinetics of bendroflumethiazide.
Beermann B, Groschinsky-Grind M, Lindstrom B. Clin Pharmacol Ther. 1977 Oct;22(4):385-8. PMID: 902450 |
902450 |
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Centyl K · Neo-Naclex-K 
Bendroza · Centyl med Kaliumklorid · Centyl Mite med Kaliumklorid 
Bendroza · Centyl med kaliumklorid · Centyl mite med kaliumklorid 
Centyl kaliumklorid · Centyl me? kaliumklorid · Centyl mite me? kaliumklorid
© NAPOS 2025